cemdomespib   Click here for help

GtoPdb Ligand ID: 13726

Synonyms: BIIB-143 | BIIB143 | compound 13b [PMID: 22702513] | compound 3 [PMID: 35905686] | KU-596 | KU596 | RTA 901 | RTA-901
Compound class: Synthetic organic
Comment: Cemdomespib (BIIB143) is an orally bioavailable small molecule modulator of heat shock (molecular chaperone) proteins with neuroprotective activity [4,6]. It contains the same noviose sugar as the antibacterial compound and heat shock protein 90 (Hsp90) C-terminal inhibitor novobiocin, making it a member of the chemical class termed "novologues" or "noviomimetics" [1]. Hsp90 molecular chaperones are regarded as targets for cancer, neurodegenerative diseases and peripheral neuropathies [7]. Inhibition of Hsp90 by novologues increases expression of Hsp70 [2-3,5]. It is this latter mechanism that is proposed to be of therapeutic benefit in treating diabetic peripheral neuropathy.
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 7
Hydrogen bond donors 3
Rotatable bonds 8
Topological polar surface area 97.25
Molecular weight 447.5
XLogP 1.05
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES CC(=O)NCCC1=CC=C(C=C1C2=CC(=CC=C2)F)O[C@H]3[C@@H]([C@@H]([C@H](C(C)(C)O3)OC)O)O
Isomeric SMILES CC(=O)NCCC1=C(C=C(C=C1)O[C@H]2[C@@H]([C@@H]([C@H](C(O2)(C)C)OC)O)O)C3=CC(=CC=C3)F
InChI InChI=1S/C24H30FNO6/c1-14(27)26-11-10-15-8-9-18(13-19(15)16-6-5-7-17(25)12-16)31-23-21(29)20(28)22(30-4)24(2,3)32-23/h5-9,12-13,20-23,28-29H,10-11H2,1-4H3,(H,26,27)/t20-,21+,22+,23+/m0/s1
InChI Key PDBWOHBMJQOBHL-WBADGQHESA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
Cemdomespib (BIIB143) was a clinical candidate for the management of diabetic peripheral neuropathic pain. Biogen decided to discontinue development for this indication in early 2025.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05895552 A Phase 2 Study of RTA 901 (BIIB143) in Participants With Diabetic Peripheral Neuropathic Pain (CYPRESS) Phase 2 Interventional Biogen